Relmada Therapeutics (OTC: RLMD), a clinical-stage biopharmaceutical company, develops novel versions of proven drug products combined with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The company has four lead products at various stages of development: d-Methadone (REL-1017), its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028), its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. For more information, visit the company’s website at www.relmada.com